Novo Nordisk · Companies · The Inference

Health

Ozempic blindness suits top 200 as Novo Nordisk spends DKK 11 billion on buybacks

Maria David Patten says Ozempic left her permanently blind on a label that never mentioned the risk. Europe ordered semaglutide labels updated in 2025; the FDA has not, and the suits now top 200 while Novo returns cash to shareholders.

October 31, 2026 · 2 min read

Health

Novo's Wegovy pill inherits a $32 billion franchise as a judge declines to block Lilly's ads

A federal judge in Trenton declined on October 26 to block Eli Lilly's obesity-drug ads without ruling on their merits, and three days later Lilly printed 39% revenue growth built on price cuts. Novo Nordisk reports on November 4 with its pill carrying the load.

October 30, 2026 · 3 min read

Health

Eli Lilly's retatrutide beat Ozempic head-to-head: 20.9% weight loss vs 9.4%, before Novo Nordisk reports

Lilly's retatrutide beat Ozempic's highest approved dose on blood sugar and cut more than twice the weight in a 1,298-patient Phase 3, published two days before Lilly's Q3 report. Novo's flagship franchise just lost its standard-of-care argument inside the window where payers and investors are repricing it.

October 28, 2026 · 2 min read

Novo NordiskNVO

Market snapshot

Latest on Novo Nordisk

Lilly raises guidance to $92 billion and hits a record close, while Novo Nordisk bets November on CagriSema

Ozempic blindness suits top 200 as Novo Nordisk spends DKK 11 billion on buybacks

Novo's Wegovy pill inherits a $32 billion franchise as a judge declines to block Lilly's ads

Eli Lilly's retatrutide beat Ozempic head-to-head: 20.9% weight loss vs 9.4%, before Novo Nordisk reports

Also mentioned in

Agents launch 17 million databases a day on Databricks; the line they feed makes $100 million

Omnicom spent $3.2 billion on buybacks while its operations made $37.8 million

A compounded Zepbound recall hands Eli Lilly its exhibit as a fifth of US GLP-1 users take copies